candesartan
Sign in to saveCandesartan is an angiotensin receptor blocker (ARB) primarily used to treat high blood pressure and congestive heart failure. It is always administered in its inactive prodrug form, candesartan cilexetil, which is converted to the active drug during absorption in the gastrointestinal tract. Like olmesartan, candesartan is a cascading prodrug, a feature that influences its pharmacokinetics. It has good bioavailability and is considered one of the most potent AT1 receptor antagonists by weight. Its effective maintenance dose is also relatively low.
Key facts
- Drug.drug_name
- Candesartan cilexetil
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 460015915
- Drug.IUPAC_name
- 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate | image = Candesartan Cilexetil.svg | image_class = skin-invert-image | synonyms = | pronounce = | tradename = Atacand, others | Drugs.com = | MedlinePlus = a601033 | pregnancy_AU = D | pregnancy_category = | legal_status = Rx-only | routes_of_administration = By mouth | bioavailability = 15% (candesartan cilexetil) | metabolism = Candesartan cilexetil: intestinal wall; candesartan: hepatic (CYP2C9) | elimination_half-life = 9 hours | excretion = Kidney 33%, faecal 67% | CAS_number_Ref = | CAS_number = 145040-37-5 | ATC_prefix = C09 | ATC_suffix = CA06 | PubChem = 2541 | IUPHAR_ligand = 8352 | DrugBank_Ref = | DrugBank = DB00796 | ChemSpiderID_Ref = | ChemSpiderID = 2444 | UNII_Ref = | UNII = R85M2X0D68 | KEGG_Ref = | KEGG = D00626 | ChEBI_Ref = | ChEBI = 3348 | ChEMBL_Ref = | ChEMBL = 1014 | C=33 | H=34 | N=6 | O=6 | smiles = CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC6 | StdInChI_Ref = | StdInChI = 1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38) | StdInChIKey_Ref = | StdInChIKey = GHOSNRCGJFBJIB-UHFFFAOYSA-N
via Wikipedia infobox
Research
3,743 papers- Candesartan.Cardiovascular drug reviews · 2004
- Candesartan for Treatment of Migraine Headache: A Scoping Review.Clinical therapeutics · 2025
- Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial.The Lancet. Neurology · 2025
- Candesartan in heart failure.Clinical interventions in aging · 2006
- Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials.International journal of stroke : official journal of the International Stroke Society · 2023
via PubMed
Article
14 sectionsContents
- Medical uses
- Hypertension
- Heart failure
- Prehypertension
- Prevention of atrial fibrillation
- Diabetic retinopathy
- Migraine prophylaxis
- Depression and bipolar depression
- Adverse effects
- Pharmacokinetics
- Research
- History
- Names
- References
Candesartan is an angiotensin receptor blocker (ARB) primarily used to treat high blood pressure and congestive heart failure. It is always administered in its inactive prodrug form, candesartan cilexetil, which is converted to the active drug during absorption in the gastrointestinal tract. Like olmesartan, candesartan is a cascading prodrug, a feature that influences its pharmacokinetics. It has good bioavailability and is considered one of the most potent AT1 receptor antagonists by weight. Its effective maintenance dose is also relatively low.
It was patented in 1990 and approved for medical use in 1997.
Gallery (2)
Connections
Categories
5-(2-phenylphenyl)-2H-tetrazole derivativesBenzimidazolesCarbonate estersCarboxylic acidsCyclohexyl compoundsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs developed by AstraZenecaDrugs developed by Takeda Pharmaceutical CompanyDrugs with non-standard legal statusECHA InfoCard ID from Wikidata